Clinical Trial Update: CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating QT-019C, a CD19 and BCMA-targeted CAR T-cell therapy, for relapse/refractory autoimmune diseases; recruitment is ongoing in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Connective Tissue Disease-associated Thrombocytopenia
• Idiopathic Inflammatory Myopathies
• Systemic Lupus Erythematosus
• Systemic Lupus Erythematosus with Immune Thrombocytopenia
• Systemic Sclerosis

Drugs mentioned

• QT-019C (CD19 and BCMA-targeted CAR T-cell therapy)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis | Phase 1 | Status: RECRUITING